Literature DB >> 28039270

Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance.

Linnell B Randall1,2, Enrico Georgi3, Gelimer H Genzel3, Herbert P Schweizer1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28039270      PMCID： PMC5890739          DOI： 10.1093/jac/dkw529

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  10 in total

1.  Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei.

Authors:  P L Ho; Terence K M Cheung; R Kinoshita; Cindy W S Tse; K Y Yuen; P Y Chau
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

2.  Oral fluoroquinolones for maintenance treatment of melioidosis.

Authors:  W Chaowagul; Y Suputtamongkul; M D Smith; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Sep-Oct       Impact factor: 2.184

Review 3.  Melioidosis.

Authors:  W Joost Wiersinga; Bart J Currie; Sharon J Peacock
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

Review 4.  Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis.

Authors:  Herbert P Schweizer
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

Review 5.  Finafloxacin: first global approval.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

6.  The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.

Authors:  Takehiko Mima; Herbert P Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

7.  Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.

Authors:  Nadine-C Emrich; Anke Heisig; Will Stubbings; Harald Labischinski; Peter Heisig
Journal:  J Antimicrob Chemother       Date:  2010-10-12       Impact factor: 5.790

8.  High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species.

Authors:  Dimitry V Viktorov; Irina B Zakharova; Maria V Podshivalova; Elena V Kalinkina; Olga A Merinova; Natalya P Ageeva; Valery A Antonov; Lyudmila K Merinova; Vladimir V Alekseev
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12       Impact factor: 2.184

Review 9.  Treatment and prophylaxis of melioidosis.

Authors:  David Dance
Journal:  Int J Antimicrob Agents       Date:  2014-02-03       Impact factor: 5.283

10.  Efflux pump-mediated drug resistance in Burkholderia.

Authors:  Nicole L Podnecky; Katherine A Rhodes; Herbert P Schweizer
Journal:  Front Microbiol       Date:  2015-04-14       Impact factor: 5.640
  10 in total
  8 in total

1.  Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression.

Authors:  Katherine A Rhodes; Nawarat Somprasong; Nicole L Podnecky; Takehiko Mima; Sunisa Chirakul; Herbert P Schweizer
Journal:  Microbiology       Date:  2018-07-19       Impact factor: 2.777

2.  A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance.

Authors:  James K Martin; Joseph P Sheehan; Benjamin P Bratton; Gabriel M Moore; André Mateus; Sophia Hsin-Jung Li; Hahn Kim; Joshua D Rabinowitz; Athanasios Typas; Mikhail M Savitski; Maxwell Z Wilson; Zemer Gitai
Journal:  Cell       Date:  2020-06-03       Impact factor: 41.582

3.  Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.

Authors:  Andreas Vente; Christine Bentley; Mark Lückermann; Paul Tambyah; Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.

Authors:  A Dalhoff; S Schubert; A Vente
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans.

Authors:  Julio Diaz Caballero; Shawn T Clark; Pauline W Wang; Sylva L Donaldson; Bryan Coburn; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  PLoS Pathog       Date:  2018-12-07       Impact factor: 6.823

6.  Demonstration of the broad spectrum in vitro activity of finafloxacin against pathogens of biodefence interest.

Authors:  Kay B Barnes; Steven D Zumbrun; Stephanie A Halasohoris; Purvi D Desai; Lynda L Miller; Mark I Richards; Paul Russell; Christine Bentley; Sarah V Harding
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

7.  GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.

Authors:  Jeffry D Shearer; Michelle L Saylor; Christine M Butler; Anthony M Treston; Henry S Heine; Sunisa Chirakul; Herbert P Schweizer; Arnold Louie; George L Drusano; Steven D Zumbrun; Kelly L Warfield
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 8.  Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.

Authors:  Béla Kocsis; Dániel Gulyás; Dóra Szabó
Journal:  Antibiotics (Basel)       Date:  2021-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.